{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T21:58:48Z","timestamp":1775858328901,"version":"3.50.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.det.2025.03.002","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T21:15:18Z","timestamp":1745442918000},"page":"461-471","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Surgical Management of Cutaneous Melanoma"],"prefix":"10.1016","volume":"43","author":[{"suffix":"Jr.","given":"Alfredo","family":"Siller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"DaCunha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brett M.","family":"Coldiron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10400","key":"10.1016\/j.det.2025.03.002_bib1","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0140-6736(23)00821-8","article-title":"Cutaneous melanoma","volume":"402","author":"Long","year":"2023","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.det.2025.03.002_bib2","doi-asserted-by":"crossref","first-page":"500","DOI":"10.5858\/arpa.2019-0561-RA","article-title":"The 2018 World Health Organization classification of cutaneous, mucosal, and uveal melanoma: detailed analysis of 9 distinct subtypes defined by their evolutionary pathway","volume":"144","author":"Elder","year":"2020","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"10.1016\/j.det.2025.03.002_bib3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.det.2025.03.002_bib4","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/annonc\/mdl490","article-title":"Detailed site distribution of melanoma and sunlight exposure: aetiological patterns from a Swiss series","volume":"18","author":"Bulliard","year":"2007","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.det.2025.03.002_bib5","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1365-2133.2006.07455.x","article-title":"Is head and neck melanoma a distinct entity? A clinical registry-based comparative study in 5702 patients with melanoma","volume":"155","author":"Hoersch","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2025.03.002_bib6","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1245\/s10434-013-2977-7","article-title":"Is head and neck melanoma different from trunk and extremity melanomas with respect to sentinel lymph node status and clinical outcome?","volume":"20","author":"Fadaki","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.det.2025.03.002_bib7","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1001\/archderm.144.4.515","article-title":"Survival differences between patients with scalp or neck melanoma and those with melanoma of other sites in the surveillance, epidemiology, and end results (SEER) program","volume":"144","author":"Lachiewicz","year":"2008","journal-title":"Arch Dermatol"},{"issue":"5","key":"10.1016\/j.det.2025.03.002_bib8","doi-asserted-by":"crossref","first-page":"895","DOI":"10.3390\/cancers16050895","article-title":"A review of contemporary guidelines and evidence for wide local excision in primary cutaneous melanoma management","volume":"16","author":"Orme","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.det.2025.03.002_bib9","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1245\/s10434-018-6470-1","article-title":"1 versus 2-cm excision margins for pT2-pT4 primary cutaneous melanoma (MelMarT): a feasibility study","volume":"25","author":"Moncrieff","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.det.2025.03.002_bib10","doi-asserted-by":"crossref","first-page":"364","DOI":"10.6004\/jnccn.2021.0018","article-title":"NCCN Guidelines\u00ae insights: melanoma: cutaneous, version 2.2021: featured updates to the NCCN guidelines","volume":"19","author":"Swetter","year":"2021","journal-title":"J Natl Compr Cancer Netw"},{"issue":"4","key":"10.1016\/j.det.2025.03.002_bib11","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/CMR.0b013e32836254bd","article-title":"Compliance with guidelines in the surgical management of cutaneous melanoma across the USA","volume":"23","author":"Wasif","year":"2013","journal-title":"Melanoma Res"},{"issue":"2","key":"10.1016\/j.det.2025.03.002_bib12","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jaad.2018.11.008","article-title":"The rule of 10s versus the rule of 2s: high complication rates after conventional excision with postoperative margin assessment of specialty site versus trunk and proximal extremity melanomas","volume":"85","author":"Rzepecki","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.det.2025.03.002_bib13","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1177\/0194599817740568","article-title":"Impact of biopsy modality on the management of cutaneous melanoma of the head and neck","volume":"158","author":"Namin","year":"2018","journal-title":"Otolaryngology-Head Neck Surg (Tokyo)"},{"issue":"10","key":"10.1016\/j.det.2025.03.002_bib14","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1111\/j.1524-4725.2012.02574.x","volume":"38","author":"Connolly","year":"2012","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.det.2025.03.002_bib15","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2147\/CCID.S137513","article-title":"Current perspectives on Mohs micrographic surgery for melanoma","volume":"11","author":"Beaulieu","year":"2018","journal-title":"Clin Cosmet Invest Dermatol"},{"issue":"3","key":"10.1016\/j.det.2025.03.002_bib16","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jaad.2021.04.090","article-title":"Systematic review and meta-analysis of local recurrence rates of head and neck cutaneous melanomas after wide local excision, Mohs micrographic surgery, or staged excision","volume":"85","author":"Bittar","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.det.2025.03.002_bib17","first-page":"660","article-title":"Mohs micrographic surgery is accurate 95.1% of the time for melanoma in situ: a prospective study of 167 cases","volume":"34","author":"Bene","year":"2008","journal-title":"Dermatol Surg"},{"issue":"3","key":"10.1016\/j.det.2025.03.002_bib18","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.jaad.2019.05.057","article-title":"Mohs micrographic surgery for melanoma: a prospective multicenter study","volume":"81","author":"Ellison","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.det.2025.03.002_bib19","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.jaad.2024.06.059","article-title":"Enhanced disease-specific survival in lentigo maligna melanoma patients treated with Mohs surgery over wide local excision: a retrospective cohort analysis of the surveillance, epidemiology, and end results database","volume":"91","author":"Taylor","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"aop","key":"10.1016\/j.det.2025.03.002_bib20","first-page":"1","article-title":"Establishing consensus for Mohs micrographic surgical techniques in the treatment of melanoma in situ for future clinical trials: a modified Delphi study","volume":"1","author":"Curtis","year":"2024","journal-title":"J Natl Compr Cancer Netw"},{"issue":"10","key":"10.1016\/j.det.2025.03.002_bib21","first-page":"914","article-title":"Cost effectiveness of Mohs micrographic surgery: review of the literature","volume":"8","author":"Tierney","year":"2009","journal-title":"J Drugs Dermatol JDD"},{"key":"10.1016\/j.det.2025.03.002_bib22","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s13671-014-0079-9","article-title":"Is Mohs surgery cost-effective versus traditional surgical excision?","volume":"3","author":"Rogers","year":"2014","journal-title":"Current Dermatology Reports"},{"issue":"7","key":"10.1016\/j.det.2025.03.002_bib23","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa1310460","article-title":"Final trial report of sentinel-node biopsy versus nodal observation in melanoma","volume":"370","author":"Morton","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.det.2025.03.002_bib24","doi-asserted-by":"crossref","first-page":"290","DOI":"10.6004\/jnccn.2024.0036","article-title":"NCCN guidelines\u00ae insights: melanoma: Cutaneous, version 2.2024: featured updates to the NCCN guidelines","volume":"22","author":"Swetter","year":"2024","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.det.2025.03.002_bib25","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1245\/ASO.2003.10.001","article-title":"Complications associated with sentinel lymph node biopsy for melanoma","volume":"10","author":"Wrightson","year":"2003","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.det.2025.03.002_bib26","series-title":"Melanoma: a modern multidisciplinary approach","author":"Riker","year":"2018"},{"issue":"11","key":"10.1016\/j.det.2025.03.002_bib27","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1002\/cncr.22320","article-title":"Accuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma","volume":"107","author":"Gannon","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.det.2025.03.002_bib28","first-page":"1097","article-title":"Wide local excision before sentinel lymph node biopsy in melanoma","volume":"10","author":"Tassavor","year":"2022","journal-title":"Dermatol Surg"},{"issue":"11","key":"10.1016\/j.det.2025.03.002_bib29","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1046\/j.1365-4362.2000.00055.x","article-title":"Sentinel node biopsy: who needs it?","volume":"39","author":"Coldiron","year":"2000","journal-title":"Int J Dermatol"},{"issue":"5","key":"10.1016\/j.det.2025.03.002_bib30","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1001\/jamaoto.2023.0076","article-title":"Association of complex lymphatic drainage in head and neck cutaneous melanoma with sentinel lymph node biopsy outcomes: a cohort study and literature review","volume":"149","author":"Pasha","year":"2023","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"Supplement_2","key":"10.1016\/j.det.2025.03.002_bib31","doi-asserted-by":"crossref","DOI":"10.1093\/bjs\/znab134.289","article-title":"489 the role of sentinel lymph node biopsy in cutaneous head and neck melanoma: a systematic review and meta-analysis","volume":"108","author":"Johnston","year":"2021","journal-title":"Br J Surg"},{"issue":"1","key":"10.1016\/j.det.2025.03.002_bib32","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000458530","article-title":"Risk and survival of patients with head and neck cutaneous melanoma: national perspective","volume":"93","author":"Al-Qurayshi","year":"2017","journal-title":"Oncology"},{"issue":"23","key":"10.1016\/j.det.2025.03.002_bib33","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","article-title":"Completion dissection or observation for sentinel-node metastasis in melanoma","volume":"376","author":"Faries","year":"2017","journal-title":"N Engl J Med"},{"issue":"32","key":"10.1016\/j.det.2025.03.002_bib34","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.18.02306","article-title":"Final analysis of DeCOG-SLT trial: no survival benefit for complete lymph node dissection in patients with melanoma with positive sentinel node","volume":"37","author":"Leiter","year":"2019","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.det.2025.03.002_bib35","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s11912-022-01289-x","article-title":"Surgical management of melanoma: advances and updates","volume":"24","author":"Santamaria-Barria","year":"2022","journal-title":"Curr Oncol Rep"},{"issue":"10","key":"10.1016\/j.det.2025.03.002_bib36","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.21873\/anticanres.16644","article-title":"The integrated i31-GEP test outperforms the MSKCC nomogram at predicting SLN status in melanoma patients","volume":"43","author":"Tassavor","year":"2023","journal-title":"Anticancer Res"},{"key":"10.1016\/j.det.2025.03.002_bib37","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1200\/PO.21.00162","article-title":"Integrating 31-gene expression profiling with clinicopathologic features to optimize cutaneous melanoma sentinel lymph node metastasis prediction","volume":"5","author":"Whitman","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"10.1016\/j.det.2025.03.002_bib38","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s10585-021-10089-9","article-title":"Sentinel lymph node biopsy in melanoma: beyond histologic factors","volume":"39","author":"Carr","year":"2022","journal-title":"Clin Exp Metastasis"},{"issue":"4","key":"10.1016\/j.det.2025.03.002_bib39","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S1470-2045(24)00076-7","article-title":"Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospective, multicentre analysis","volume":"25","author":"Stassen","year":"2024","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.det.2025.03.002_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100136","article-title":"How we treat locoregional melanoma","volume":"6","author":"Troiani","year":"2021","journal-title":"ESMO open"},{"issue":"3","key":"10.1016\/j.det.2025.03.002_bib41","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.ejso.2016.10.005","article-title":"Diagnosis and treatment of in-transit melanoma metastases","volume":"43","author":"Testori","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.det.2025.03.002_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-019-0623-z","article-title":"Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III\u2013IV melanoma","volume":"7","author":"Andtbacka","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.det.2025.03.002_bib43","series-title":"Surgical management of melanoma","first-page":"91","author":"Joyce","year":"2017"},{"issue":"10304","key":"10.1016\/j.det.2025.03.002_bib44","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.det.2025.03.002_bib45","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.det.2025.03.002_bib46","series-title":"Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: new recurrence-free survival results from the EORTC 1325-MG\/Keynote 054 double-blinded phase III trial at three-year median follow-up","author":"Eggermont","year":"2020"},{"issue":"19","key":"10.1016\/j.det.2025.03.002_bib47","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.det.2025.03.002_bib48","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB\u2013C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial","volume":"21","author":"Ascierto","year":"2020","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1016\/j.det.2025.03.002_bib49","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","article-title":"Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma","volume":"391","author":"Blank","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.det.2025.03.002_bib50","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant\u2013adjuvant or adjuvant-only pembrolizumab in advanced melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.det.2025.03.002_bib51","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1038\/s41591-023-02583-2","article-title":"Adjuvant nivolumab in resected stage IIB\/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial","volume":"29","author":"Kirkwood","year":"2023","journal-title":"Nat Med"},{"issue":"14","key":"10.1016\/j.det.2025.03.002_bib52","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.det.2025.03.002_bib53","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.det.2025.03.002_bib54","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1200\/JCO.2010.33.9275","article-title":"Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification","volume":"29","author":"Guo","year":"2011","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.det.2025.03.002_bib55","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1200\/JCO.2012.47.7836","article-title":"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin","volume":"31","author":"Hodi","year":"2013","journal-title":"J Clin Oncol"},{"issue":"7688","key":"10.1016\/j.det.2025.03.002_bib56","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nature25187","article-title":"High response rate to PD-1 blockade in desmoplastic melanomas","volume":"553","author":"Eroglu","year":"2018","journal-title":"Nature"},{"issue":"14","key":"10.1016\/j.det.2025.03.002_bib57","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.3390\/cancers16142572","article-title":"Clinical and imaging follow-up for high-risk cutaneous melanoma: current evidence and guidelines","volume":"16","author":"Vetto","year":"2024","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.det.2025.03.002_bib58","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jaad.2018.08.055","article-title":"Guidelines of care for the management of primary cutaneous melanoma","volume":"80","author":"Swetter","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.det.2025.03.002_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-1-62","article-title":"F-18-fluoro-2-deoxyglucose positron emission tomography (PET) and PET\/computed tomography imaging in primary staging of patients with malignant melanoma: a systematic review","volume":"1","author":"Schr\u00f6er-G\u00fcnther","year":"2012","journal-title":"Syst Rev"},{"issue":"7","key":"10.1016\/j.det.2025.03.002_bib60","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1093\/neuonc\/noae049","article-title":"Challenges, limitations, and pitfalls of PET and advanced MRI in patients with brain tumors: a report of the PET\/RANO group","volume":"26","author":"Galldiks","year":"2024","journal-title":"Neuro Oncol"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863525000166?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863525000166?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T21:44:19Z","timestamp":1750974259000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863525000166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0733863525000166"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2025.03.002","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Surgical Management of Cutaneous Melanoma","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2025.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}